Table3.

Examples of MET inhibitors in clinical trials

Drug	Target	Phase	Study population	Clinicaltrials.gov
Selective MET inhibitors
Capmatinib (INC280)	MET	1	Dose expansion MET-aberrant solid tumors	NCT01324479
	MET	2	EGFR wild type NSCLC after one or two prior lines of chemotherapy	NCT02414139
SAR125844	MET	2	MET-amplified tumors	NCT02435121
Multikinase inhibitors
Crizotinib	MET, ALK, ROS1, NTRK	2	CREATE: ALK/MET Cross-tumor	NCT01524926
Cabozantinib	MET, AXL, VEGFR, RET, ROS1, KIT, NTRK1-3	2	NSCLC with brain metastasis+/-MET amplification	NCT01232598
			Genotypically selected NSCLC	NCT01639508
MGCD516	MET, AXL, VEGFR, RET, PDGFR, DDR2, KIT, NTRK1-3	1	Dose expansion in Genotypically selected NSCLC	NCT02219711
Altiratinib (DCC-2701)	MET, VEGFR2, NTRK1-3	1	Solid tumors	NCT02228811